Delineating Spatiotemporal and Hierarchical Development of Human Fetal Innate Lymphoid Cells
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse
Welcome to More Choice CD Marker Handbook For more information, please visit: Human bdbiosciences.com/eu/go/humancdmarkers Mouse bdbiosciences.com/eu/go/mousecdmarkers Human and Mouse CD Marker Handbook Human and Mouse CD Marker Key Markers - Human Key Markers - Mouse CD3 CD3 CD (cluster of differentiation) molecules are cell surface markers T Cell CD4 CD4 useful for the identification and characterization of leukocytes. The CD CD8 CD8 nomenclature was developed and is maintained through the HLDA (Human Leukocyte Differentiation Antigens) workshop started in 1982. CD45R/B220 CD19 CD19 The goal is to provide standardization of monoclonal antibodies to B Cell CD20 CD22 (B cell activation marker) human antigens across laboratories. To characterize or “workshop” the antibodies, multiple laboratories carry out blind analyses of antibodies. These results independently validate antibody specificity. CD11c CD11c Dendritic Cell CD123 CD123 While the CD nomenclature has been developed for use with human antigens, it is applied to corresponding mouse antigens as well as antigens from other species. However, the mouse and other species NK Cell CD56 CD335 (NKp46) antibodies are not tested by HLDA. Human CD markers were reviewed by the HLDA. New CD markers Stem Cell/ CD34 CD34 were established at the HLDA9 meeting held in Barcelona in 2010. For Precursor hematopoetic stem cell only hematopoetic stem cell only additional information and CD markers please visit www.hcdm.org. Macrophage/ CD14 CD11b/ Mac-1 Monocyte CD33 Ly-71 (F4/80) CD66b Granulocyte CD66b Gr-1/Ly6G Ly6C CD41 CD41 CD61 (Integrin b3) CD61 Platelet CD9 CD62 CD62P (activated platelets) CD235a CD235a Erythrocyte Ter-119 CD146 MECA-32 CD106 CD146 Endothelial Cell CD31 CD62E (activated endothelial cells) Epithelial Cell CD236 CD326 (EPCAM1) For Research Use Only. -
Anti-NCR1 Antibody [29A1.4] (FITC) (ARG23568)
Product datasheet [email protected] ARG23568 Package: 50 μg anti-NCR1 antibody [29A1.4] (FITC) Store at: 4°C Summary Product Description FITC-conjugated Rat Monoclonal antibody [29A1.4] recognizes NCR1. Rat anti Mouse CD335 antibody, clone 29A1.4 recognizes natural killer cell p46-related protein (NKp46), otherwise known as CD335, which is uniquely expressed by resting and activated natural killer (NK) cells, but no expression of CD335 has been detected on B cells, T cells, monocytes or granulocytes. It is a major NK cell lysis receptor for autologous pathogen-infected and tumor target cells during natural cytotoxicity responses. Ligands of CD335 include viral hemagglutinins (HAs) and heparan sulfate proteoglycans (HSPGs) on the surface of tumor cells. Staining with Rat anti mouse CD335 (29A1.4) is not strain specific and the antibody has been used to stain C57BL/6, SJL, CBA/CA and BALB/c strains. Clone 29A1.4 also activates NK cells in vitro. It does not deplete NK cells in vivo. Tested Reactivity Ms Tested Application FACS Host Rat Clonality Monoclonal Clone 29A1.4 Isotype IgG2a Target Name NCR1 Antigen Species Mouse Immunogen NKP46-IgG1 Fc fusion protein. Conjugation FITC Alternate Names CD antigen CD335; Natural killer cell p46-related protein; Lymphocyte antigen 94 homolog; Natural cytotoxicity triggering receptor 1; hNKp46; NKP46; NKp46; NK cell-activating receptor; LY94; CD335; NK- p46 Application Instructions Application table Application Dilution FACS 1:2 - 1:5 Application Note FACS: Use 10 µl of the suggested working dilution to label 10^6 cells in 100 µl. * The dilutions indicate recommended starting dilutions and the optimal dilutions or concentrations should be determined by the scientist. -
Receptor Nkp46 Cells by the NK Β Murine Pancreatic Recognition And
Recognition and Killing of Human and Murine Pancreatic β Cells by the NK Receptor NKp46 This information is current as Chamutal Gur, Jonatan Enk, Sameer A. Kassem, Yaron of September 27, 2021. Suissa, Judith Magenheim, Miri Stolovich-Rain, Tomer Nir, Hagit Achdout, Benjamin Glaser, James Shapiro, Yaakov Naparstek, Angel Porgador, Yuval Dor and Ofer Mandelboim J Immunol 2011; 187:3096-3103; Prepublished online 17 Downloaded from August 2011; doi: 10.4049/jimmunol.1101269 http://www.jimmunol.org/content/187/6/3096 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2011/08/18/jimmunol.110126 Material 9.DC1 References This article cites 29 articles, 9 of which you can access for free at: http://www.jimmunol.org/content/187/6/3096.full#ref-list-1 Why The JI? Submit online. by guest on September 27, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2011 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Recognition and Killing of Human and Murine Pancreatic b Cells by the NK Receptor NKp46 Chamutal Gur,*,†,1 Jonatan Enk,*,1 Sameer A. -
Receptor Nkp46/NCR1 Tumors in the Absence of the NK-Activating
The Journal of Immunology Enhanced In Vivo Growth of Lymphoma Tumors in the Absence of the NK-Activating Receptor NKp46/NCR11 Gili G. Halfteck, Moran Elboim, Chamutal Gur, Hagit Achdout, Hormas Ghadially, and Ofer Mandelboim2 The in vitro elimination of virus-infected and tumor cells by NK cells is regulated by a balance between signals conveyed via specific inhibitory and activating receptors. Whether NK cells and specifically the NK-activating receptor NKp46 (NCR1 in mice) are directly involved in tumor eradication in vivo is still largely unknown. Since the NKp46/NCR1 tumor ligands have not been identified yet, we use a screening technique to identify functional ligands for NKp46/NCR1 which is based on a cell reporter assay and discover a NCR1 ligand in the PD1.6 lymphoma line. To study whether NKp46/NCR1 is important for the eradication of PD1.6 lymphoma in vivo, we used the Ncr1 knockout Ncr1gfp/gfp mice generated by our group. Strikingly, all Ncr1 knockout mice developed growing PD1.6 tumors, whereas initial tumor growth was observed in the wild-type mice and tumors were completely rejected as time progressed. The growth of other lymphoma cell lines such as B10 and EL4 was equivalent between the Ncr1 knockout and wild-type mice. Finally, we show that PD1.6 lymphoma cells are less killed both in vitro and in vivo in the absence of NKp46/NCR1. Our results therefore reveal a crucial role for NKp46/NCR1 in the in vivo eradication of some lymphoma cells. The Journal of Immunology, 2009, 182: 2221–2230. t was hypothesized that the immune system surveys the body reduced resistance to transplanted tumor cell lines (20–22). -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Flow Reagents Single Color Antibodies CD Chart
CD CHART CD N° Alternative Name CD N° Alternative Name CD N° Alternative Name Beckman Coulter Clone Beckman Coulter Clone Beckman Coulter Clone T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells T Cells B Cells Granulocytes NK Cells Macrophages/Monocytes Platelets Erythrocytes Stem Cells Dendritic Cells Endothelial Cells Epithelial Cells CD1a T6, R4, HTA1 Act p n n p n n S l CD99 MIC2 gene product, E2 p p p CD223 LAG-3 (Lymphocyte activation gene 3) Act n Act p n CD1b R1 Act p n n p n n S CD99R restricted CD99 p p CD224 GGT (γ-glutamyl transferase) p p p p p p CD1c R7, M241 Act S n n p n n S l CD100 SEMA4D (semaphorin 4D) p Low p p p n n CD225 Leu13, interferon induced transmembrane protein 1 (IFITM1). p p p p p CD1d R3 Act S n n Low n n S Intest CD101 V7, P126 Act n p n p n n p CD226 DNAM-1, PTA-1 Act n Act Act Act n p n CD1e R2 n n n n S CD102 ICAM-2 (intercellular adhesion molecule-2) p p n p Folli p CD227 MUC1, mucin 1, episialin, PUM, PEM, EMA, DF3, H23 Act p CD2 T11; Tp50; sheep red blood cell (SRBC) receptor; LFA-2 p S n p n n l CD103 HML-1 (human mucosal lymphocytes antigen 1), integrin aE chain S n n n n n n n l CD228 Melanotransferrin (MT), p97 p p CD3 T3, CD3 complex p n n n n n n n n n l CD104 integrin b4 chain; TSP-1180 n n n n n n n p p CD229 Ly9, T-lymphocyte surface antigen p p n p n -
Expression and Function of Nkp46 W32R
www.nature.com/scientificreports OPEN Expression and function of NKp46 W32R: the human homologous protein of mouse NKp46 W32R Received: 14 October 2016 Accepted: 12 December 2016 (Noé) Published: 30 January 2017 Ariella Glasner, Batya Isaacson & Ofer Mandelboim Natural killer (NK) cells eradicate infected cells and tumors following the triggering of activating receptors, like the Natural Cytotoxicity Receptors (NCRs), which include NKp30, NKp44 and NKp46. NKp46 is the only NCR expressed in mice (mNKp46), and except for some Innate Lymphoid Cell (ILC) populations (ILC1/3 subsets), its expression is restricted to NK cells. Previously, a mouse named Noé was generated in which a random point mutation (W32R) impaired the cell surface expression of mNKp46. Interestingly, the Noé mice NK cells expressed twice as much of the transcription factor Helios, and displayed general non-NKp46 specific hyperactivity. We recently showed that the mNKp46 W32R (Noé) protein was expressed on the surface of various cells; albeit slowly and unstably, that it is aberrantly glycosylated and accumulates in the ER. Interestingly, the Tryptophan (Trp) residue in position 32 is conserved between humans and mice. Therefore, we studied here the human orthologue protein of mNKp46 W32R, the human NKp46 W32R. We demonstrated that NKp46 W32R is aberrantly glycosylated, accumulates in the ER, and is unstable on the cell surface. Furthermore, we showed that overexpression of NKp46 W32R or Helios resulted in augmented NK cell activation, which may be applied to boost NK activity for therapeutic applications. NK cells are innate lymphocytes, lately characterized as group I innate lymphoid cells (ILCs). They specialize in the eradication of various pathogens and cancers1–12. -
The Poliovirus Receptor (CD155)
Cutting Edge: CD96 (Tactile) Promotes NK Cell-Target Cell Adhesion by Interacting with the Poliovirus Receptor (CD155) This information is current as Anja Fuchs, Marina Cella, Emanuele Giurisato, Andrey S. of September 27, 2021. Shaw and Marco Colonna J Immunol 2004; 172:3994-3998; ; doi: 10.4049/jimmunol.172.7.3994 http://www.jimmunol.org/content/172/7/3994 Downloaded from References This article cites 19 articles, 8 of which you can access for free at: http://www.jimmunol.org/content/172/7/3994.full#ref-list-1 http://www.jimmunol.org/ Why The JI? Submit online. • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication by guest on September 27, 2021 *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2004 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. THE JOURNAL OF IMMUNOLOGY CUTTING EDGE Cutting Edge: CD96 (Tactile) Promotes NK Cell-Target Cell Adhesion by Interacting with the Poliovirus Receptor (CD155) Anja Fuchs, Marina Cella, Emanuele Giurisato, Andrey S. Shaw, and Marco Colonna1 The poliovirus receptor (PVR) belongs to a large family of activating receptor DNAM-1, also called CD226 (6, 7). -
Targeting HIF-1 Alpha Transcriptional Activity Drives Cytotoxic Immune Effector Cells Into Melanoma and Improves Combination Immunotherapy
Oncogene (2021) 40:4725–4735 https://doi.org/10.1038/s41388-021-01846-x BRIEF COMMUNICATION Targeting HIF-1 alpha transcriptional activity drives cytotoxic immune effector cells into melanoma and improves combination immunotherapy 1 1 1 1 1 Audrey Lequeux ● Muhammad Zaeem Noman ● Malina Xiao ● Kris Van Moer ● Meriem Hasmim ● 1 1 1 1 1,2 3,4 Alice Benoit ● Manon Bosseler ● Elodie Viry ● Tsolere Arakelian ● Guy Berchem ● Salem Chouaib ● Bassam Janji 1 Received: 31 August 2020 / Revised: 27 April 2021 / Accepted: 17 May 2021 / Published online: 21 June 2021 © The Author(s) 2021. This article is published with open access Abstract Hypoxia is a key factor responsible for the failure of therapeutic response in most solid tumors and promotes the acquisition of tumor resistance to various antitumor immune effectors. Reshaping the hypoxic immune suppressive tumor microenvironment to improve cancer immunotherapy is still a relevant challenge. We investigated the impact of inhibiting HIF-1α transcriptional activity on cytotoxic immune cell infiltration into B16-F10 melanoma. We showed that tumors 1234567890();,: 1234567890();,: expressing a deleted form of HIF-1α displayed increased levels of NK and CD8+ effector T cells in the tumor microenvironment, which was associated with high levels of CCL2 and CCL5 chemokines. We showed that combining acriflavine, reported as a pharmacological agent preventing HIF-1α/HIF-1β dimerization, dramatically improved the benefit of cancer immunotherapy based on TRP-2 peptide vaccination and anti-PD-1 blocking antibody. In melanoma patients, we revealed that tumors exhibiting high CCL5 are less hypoxic, and displayed high NK, CD3+, CD4+ and CD8+ T cell markers than those having low CCL5. -
Chem. Pharm. Bull. 51(10) 1217ム1219
October 2003 Communications to the Editor Chem. Pharm. Bull. 51(10) 1217—1219 (2003) 1217 A New Application of Sequence Fourier Of biologically active proteins,3) we first focused on the analytical results (Figs. 1a, b) derived from the naturally oc- Analysis to Specific Ligand–Protein curring (i.e., sense) amino acid sequence of bovine adreno- Interactions corticotropic hormone (ACTH) (bACTH; 24aa),4) and from the antisense peptide encoded by a nucleotide sequence com- ,a b Naganori NUMAO,* Hisashi FUJII, plementary to the mRNA for bACTH. Their specific interac- b c Yoshiyuki FUKAZAWA, and Kazuyoshi TANAKA tion has experimentally been observed by Blalock and his 5) a BioFrontier Institute Inc.; 5–4–21 Nishi-Hashimoto, Sagamihara, colleagues, but this work is still controversial. Interestingly, 5 Kanagawa 229–1131, Japan: b Kanagawa Industrial Technology two characteristic peaks ( f 0.1719 and 0.3281, where f sig- Research Institute; 705–1 Shimoimaizumi Ebina, Kanagawa nifies the frequency value by the sequence Fourier analysis in 243–0435, Japan: and c Department of Molecular Engineering ref. 1) are observed as major peaks in both the figures. Graduate School of Engineering, Kyoto University; Nishikyo-ku, In the course of investigating various ligand-receptor inter- Kyoto 615–8500, Japan. actions,6) we next happened to notice that two characteristic Received July 2, 2003; accepted August 4, 2003 peaks ( f50.0313, 0.4688) in the spectra derived from both the sense- and the antisense-amino acid sequences (Figs. 2a, A frequency (or sequence)-dependent rule seems to be con- b, respectively) of human calcitonin (hCT; 32aa) are in close served in a simple and concerted interaction of various human proximity to those ( f 5ca. -
Arming Tumor-Associated Macrophages to Reverse Epithelial
Published OnlineFirst August 15, 2019; DOI: 10.1158/0008-5472.CAN-19-1246 Cancer Tumor Biology and Immunology Research Arming Tumor-Associated Macrophages to Reverse Epithelial Cancer Progression Hiromi I.Wettersten1,2,3, Sara M.Weis1,2,3, Paulina Pathria1,2,Tami Von Schalscha1,2,3, Toshiyuki Minami1,2,3, Judith A. Varner1,2, and David A. Cheresh1,2,3 Abstract Tumor-associated macrophages (TAM) are highly expressed it engaged macrophages but not natural killer (NK) cells to within the tumor microenvironment of a wide range of cancers, induce antibody-dependent cellular cytotoxicity (ADCC) of where they exert a protumor phenotype by promoting tumor avb3-expressing tumor cells despite their expression of the cell growth and suppressing antitumor immune function. CD47 "don't eat me" signal. In contrast to strategies designed Here, we show that TAM accumulation in human and mouse to eliminate TAMs, these findings suggest that anti-avb3 tumors correlates with tumor cell expression of integrin avb3, represents a promising immunotherapeutic approach to redi- a known driver of epithelial cancer progression and drug rect TAMs to serve as tumor killers for late-stage or drug- resistance. A monoclonal antibody targeting avb3 (LM609) resistant cancers. exploited the coenrichment of avb3 and TAMs to not only eradicate highly aggressive drug-resistant human lung and Significance: Therapeutic antibodies are commonly engi- pancreas cancers in mice, but also to prevent the emergence neered to optimize engagement of NK cells as effectors. In of circulating tumor cells. Importantly, this antitumor activity contrast, LM609 targets avb3 to suppress tumor progression in mice was eliminated following macrophage depletion. -
Tumor-Responsive, Multifunctional CAR-NK Cells Cooperate with Impaired Autophagy to Infiltrate and Target Glioblastoma
bioRxiv preprint doi: https://doi.org/10.1101/2020.10.07.330043; this version posted October 8, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Tumor-responsive, multifunctional CAR-NK cells cooperate with impaired autophagy to infiltrate and target glioblastoma Jiao Wang1, Sandra Toregrosa-Allen2, Bennett D. Elzey2, Sagar Utturkar2, Nadia Atallah Lanman2,3, Victor Bernal-Crespo4, Matthew M. Behymer1, Gregory T. Knipp1, Yeonhee Yun5, Michael C. Veronesi5, Anthony L. Sinn6, Karen E. Pollok6,7,8,9, Randy R. Brutkiewicz10, Kathryn S. Nevel11, Sandro Matosevic1,2* 1Department of Industrial and Physical Pharmacy, Purdue University, West Lafayette, IN, USA 2Center for Cancer Research, Purdue University, West Lafayette, IN, USA 3Department of Comparative Pathobiology, Purdue University, West Lafayette, IN, USA 4Histology Research Laboratory, Center for Comparative Translational Research, College of Veterinary Medicine, Purdue University, West Lafayette, IN, USA. 5Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA 6In Vivo Therapeutics Core, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA 7Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis, IN, USA 8Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of